RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Yahoo Finance
5 days ago • Google News
Biogen Inc (BIIB)
US$ 126.3-0.41%
Price Chart
Key Statistics
Market Cap
$ 19.5B
P/E Ratio
13.15
Revenue (TTM)
$ 9.82B
Volume
917.68K
52W High
$ 236.48
52W Low
$ 110.04
Dividend Yield
0.00%
Beta
0.15
Technicals
50-Day MA
127.9996
200-Day MA
146.2958
52 Week High
236.48
52 Week Low
110.04
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Employees
7605
Headquarters
Cambridge, MA
CEO
Mr. Christopher A. Viehbacher
Latest News
When (BIIB) Moves Investors should Listen - news.stocktradersdaily.com
2 days ago • Google News
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Insider Monkey
5 days ago • Google News
Environment, Social and Governance (ESG) Risk Ratings
Total ESG Risk Score
22.95
Percentile: 33.82
Environmental Risk Score
1.02
Percentile: 2
Social Risk Score
13.48
Percentile: 2
Governance Risk Score
7.45
Percentile: 2
Controversy Level
ESG data provided by Sustainalytics, Inc.
BIIB
Category Average
2Moderate Controversy Level
NoneSevere
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg